More tools:Markets·Screener·Research·Chat

Moleculin Biotech, Inc. (MBRX) Financial Statements

Moleculin Biotech, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00B9T47N7
XNAS · usd
0.75▲ 0.04 (5.66%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close0.71
Day's Range0.72 – 0.80
52-Week Range0.16 – 7.98
Volume733.3K
Avg Volume1.8M
Share Statistics
Shares Outstanding
Employees17
ExchangeXNAS
Listed2016-06-02
Share count as of August 6, 2026
Loading Income Statement…
Key questions about Moleculin Biotech, Inc. (MBRX)
What is Moleculin Biotech, Inc.'s Market Cap?
Moleculin Biotech, Inc.'s Market Cap is $14.6M, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s Enterprise Value?
Moleculin Biotech, Inc.'s Enterprise Value is $7.3M, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s EV / EBITDA?
Moleculin Biotech, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s Revenue (TTM)?
Moleculin Biotech, Inc.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s Net Income (TTM)?
Moleculin Biotech, Inc.'s Net Income (TTM) is -$30.3M, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s EBITDA?
Moleculin Biotech, Inc.'s EBITDA is -$28.8M, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s Diluted EPS (TTM)?
Moleculin Biotech, Inc.'s Diluted EPS (TTM) is -1.56, based on as-reported figures from SEC (XBRL) filings.
What is Moleculin Biotech, Inc.'s Net Debt?
Moleculin Biotech, Inc.'s Net Debt is -$7.3M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Operating expenses:
Research and development
General and administrative
Depreciation and amortization
Total operating expenses
Loss from operations
Other income (loss):
Gain (loss) from change in fair value of warrant liability
Transaction costs allocated to warrant liabilities
Loss on issuance of warrant liabilities
Other income, net
Interest income (expense), net
Net loss
Warrant deemed dividend——
Net loss available to common stockholders——
Net loss per common share - basic and diluted (in dollars per share)—